VIKING THERAPEUTICS INC. news, videos and press releases
For more news please use our advanced search feature.
VIKING THERAPEUTICS INC. - More news...
VIKING THERAPEUTICS INC. - More news...
- Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
- CordenPharma and Viking Therapeutics Sign Long-Term Strategic Partnership for Integrated Supply of GLP-1 Peptides, Injectables and Oral Formulations
- Viking Therapeutics Signs Broad Manufacturing Agreement With CordenPharma to Support Commercialization of VK2735
- Viking Therapeutics to Participate at Upcoming Investor Conferences
- Viking Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update
- Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2024 on February 5, 2025
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX
- Viking Therapeutics Announces Initiation of Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
- Viking Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX
- Viking Therapeutics Presents Results from Phase 2b VOYAGE Study of VK2809 in Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX
- Viking Therapeutics to Present Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024
- Viking Therapeutics Reports New Data from VK2735 Obesity Program at ObesityWeek® 2024
- Viking Therapeutics to Participate at Upcoming Investor Conferences
- Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek® 2024
- Viking Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
- Viking Therapeutics to Report Financial Results for Third Quarter 2024 on October 23, 2024
- Viking Therapeutics Announces Results from Phase 1b Clinical Trial of VK0214 in Patients with X-ALD
- Viking Therapeutics to Participate at Morgan Stanley 22nd Annual Global Healthcare Conference
- Viking Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
- Viking Therapeutics to Report Financial Results for Second Quarter 2024 on July 24, 2024
- Viking Therapeutics Presents Preclinical Data on Novel Dual Amylin and Calcitonin Receptor Agonists at 84th Scientific Sessions of the American Diabetes Association
- Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
- Viking Therapeutics to Participate at Upcoming Investor Conferences
- Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
